Are peptides legal? What the FDA says about 18 peptides
Peptides are legal in the US as an FDA-approved drug, or compounded by a licensed pharmacy for one patient on a valid prescription under section 503A (21 U.S.C. 353a). An HHS policy dated October 28, 2026 covers BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax under conditions. Each line below quotes the linked FDA page, with that page's date. Last checked November 19, 2026. This page is information only.
Where the FDA decision stands, November 19, 2026
- On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to discuss seven peptides being considered for the 503A bulks list: BPC-157, KPV, TB-500 and MOTS-c on the first day, and DSIP (emideltide), semax and epitalon on the second. Source
- The FDA says its advisory committees make non-binding recommendations, which it generally follows but is not legally bound to. Source
- As of November 19, 2026, none of the seven is named on the FDA's 503A categories list, last updated May 14, 2026. Source
- The FDA's Category 2 page, current as of April 22, 2026, lists BPC-157 among the substances whose nominations were withdrawn. Source
October 28, 2026: HHS will not act against some compounded peptides, under conditions
HHS filed a notice on October 28, 2026 of a policy for six peptides used in 503A compounding: BPC-157, TB-500, MOTS-c, epitalon, KPV and semax. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds them and meets the policy's conditions.
It is not FDA approval, and it does not put the six on the 503A bulks list, which is still being written by rulemaking. It binds no one, and HHS may revisit it in whole or in part. It names pharmacies, federal facilities and physicians only: nothing in it covers 503B outsourcing facilities, "research use only" chemicals or supplements.
The conditions include an FDA-registered maker of the raw ingredient that follows current good manufacturing practice, with a certificate of analysis; one peptide per product; serious adverse events reported to FDA's MedWatch; and a label that reads "This is a compounded drug product. Not for resale."
The Federal Register published the notice on October 30, 2026, with comments open for two weeks after that (about November 13, 2026, our estimate). CJC-1295, ipamorelin and GHK-Cu are not among the six.
Read the HHS notice on the Federal RegisterWhat changed and what did not, Peptide seller checklist
Cheapest sermorelin on our chart
Tied at $99 a month: CoreAge Rx, Embody, Lttl, Strut Health and Villas Health.
CoreAge Rxfrom $99 a month, no membership fee. No long-term contractSermorelin injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
Embody$99 a month, after a $49 first monthSermorelin injectionChecked November 21, 2026 on Embody's own pageCheck price at Embody →
Lttlfrom $99 a month, visits included. The plan is set at checkoutSermorelin injectionChecked November 21, 2026 on Lttl's own pageCheck price at Lttl →
Strut Health$99 a month, on auto-refillSermorelin lozengeChecked November 21, 2026 on Strut Health's own pageCheck price at Strut Health →
Villas Health$99 a month, monthly subscription; $119 as a one-time purchaseSermorelin injectionChecked November 21, 2026 on Villas Health's own pageSee prices
Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money
BPC-157
The FDA lists BPC-157 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. BPC-157 is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as BPC-157 acetate in injection, oral and topical forms. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). BPC-157 status page
TB-500
TB-500 is thymosin beta-4 fragment (LKKTETQ). The FDA lists it among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. It is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as TB-500 acetate in injection only. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). TB-500 status page
MOTS-c
The FDA lists MOTs-C among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. It is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as MOTS-c acetate in injection only. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). MOTS-c status page
Epitalon
The FDA lists epitalon among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. Epitalon is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as Epitalon acetate in injection only, dispensed in intermittent courses. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Epitalon status page
KPV
The FDA lists KPV among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. The FDA says it has found no human exposure data on KPV by any route. KPV is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as KPV acetate in topical and oral forms only. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). KPV status page
Semax
The FDA lists semax (heptapeptide) among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. Semax is not named on the FDA's 503A category lists.
HHS 503A policy: covered from October 28, 2026, under conditions, as Semax free base in nasal use only. Not FDA approval.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Semax status page
GHK-Cu
For injection, the FDA lists GHK-Cu among substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. For other routes, GHK-Cu is on the FDA's Category 1 list, and the FDA says it intends to ask its compounding advisory committee about GHK-Cu before the end of February 2027.
Not covered by the October 28, 2026 HHS policy. What the policy covers
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). GHK-Cu status page
CJC-1295
The FDA lists CJC-1295 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. CJC-1295 is not named on the FDA's 503A category lists.
Not covered by the October 28, 2026 HHS policy. What the policy covers
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). CJC-1295 status page
Ipamorelin
Under the FDA's 503B interim policy, ipamorelin acetate has been in Category 2, the FDA's list of substances that may present significant safety risks, since September 29, 2023. A second nomination of ipamorelin is listed as withdrawn. It is not named on the FDA's 503A category lists.
Not covered by the October 28, 2026 HHS policy. What the policy covers
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Ipamorelin status page
DSIP
The FDA lists emideltide (DSIP) among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. DSIP is not named on the FDA's 503A category lists.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). DSIP status page
Selank
The FDA lists selank acetate (TP-7) among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. Selank is not named on the FDA's 503A category lists.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Selank status page
Kisspeptin-10
Kisspeptin-10 is on the FDA's 503A Category 2 list, bulk drug substances that raise significant safety risks, since September 29, 2023.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Kisspeptin-10 status page
AOD-9604
The FDA lists AOD-9604 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. AOD-9604 is not named on the FDA's 503A category lists.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). AOD-9604 status page
Melanotan II
The FDA lists Melanotan II among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. Melanotan II is not named on the FDA's 503A category lists.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). Melanotan II status page
LL-37
The FDA lists cathelicidin LL-37 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. LL-37 is not named on the FDA's 503A category lists.
Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026). LL-37 status page
Sermorelin
The brand Geref was approved and discontinued, not withdrawn for safety.
Source: approved and discontinued. Our Sermorelin price page
NAD+
NAD is on the FDA's Category 1 list, substances pharmacies may compound while the agency reviews them.
Glutathione
Glutathione is on the FDA's Category 1 list, substances pharmacies may compound while the agency reviews them.
Source: the FDA's Category 1 list. Our Glutathione price page
Questions
Are peptides legal in the US?
A peptide reaches US patients legally as an FDA-approved drug, or compounded by a licensed pharmacist for an identified patient on a valid prescription under section 503A (21 U.S.C. 353a). HHS's policy dated October 28, 2026 (91 FR 68526) covers BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax for 503A compounding, under conditions. Checked November 19, 2026.
Is BPC-157 legal?
The FDA lists BPC-157 among bulk drug substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. BPC-157 is not named on the FDA's 503A category lists. The October 28, 2026 HHS policy covers BPC-157 acetate in injection, oral and topical forms, under conditions. That is not FDA approval.
Is sermorelin legal?
The brand Geref was approved and discontinued, not withdrawn for safety. It needs a prescription.
Can you buy peptides legally?
With a prescription, from a program that fills it at a state-licensed US pharmacy. Our seller checklist records, for every program on the chart, whether it names its pharmacy, requires a prescription and has an FDA warning letter.
The HHS 503A peptide policy, explained, Our commentary on the HHS notice, Peptide seller checklist, Where to buy peptides legally, What is dated to change in 2027